226 related articles for article (PubMed ID: 12410858)
1. Losartan in patients with type 2 diabetes and proteinuria: observations from the RENAAL Study.
Shahinfar S; Dickson TZ; Ahmed T; Zhang Z; Ramjit D; Smith RD; Brenner BM;
Kidney Int Suppl; 2002 Dec; (82):S64-7. PubMed ID: 12410858
[TBL] [Abstract][Full Text] [Related]
2. Losartan reduces the burden and cost of ESRD: public health implications from the RENAAL study for the European Union.
Gerth WC; Remuzzi G; Viberti G; Hannedouche T; Martinez-Castelao A; Shahinfar S; Carides GW; Brenner B
Kidney Int Suppl; 2002 Dec; (82):S68-72. PubMed ID: 12410859
[TBL] [Abstract][Full Text] [Related]
3. Losartan and end-organ protection--lessons from the RENAAL study.
Kowey PR; Dickson TZ; Zhang Z; Shahinfar S; Brenner BM;
Clin Cardiol; 2005 Mar; 28(3):136-42. PubMed ID: 15813620
[TBL] [Abstract][Full Text] [Related]
4. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL.
de Zeeuw D; Remuzzi G; Parving HH; Keane WF; Zhang Z; Shahinfar S; Snapinn S; Cooper ME; Mitch WE; Brenner BM
Kidney Int; 2004 Jun; 65(6):2309-20. PubMed ID: 15149345
[TBL] [Abstract][Full Text] [Related]
5. Renin angiotensin aldosterone system blockade and renal disease in patients with type 2 diabetes: a subanalysis of Japanese patients from the RENAAL study.
Kurokawa K; Chan JC; Cooper ME; Keane WF; Shahinfar S; Zhang Z
Clin Exp Nephrol; 2006 Sep; 10(3):193-200. PubMed ID: 17009077
[TBL] [Abstract][Full Text] [Related]
6. Design of combination angiotensin receptor blocker and angiotensin-converting enzyme inhibitor for treatment of diabetic nephropathy (VA NEPHRON-D).
Fried LF; Duckworth W; Zhang JH; O'Connor T; Brophy M; Emanuele N; Huang GD; McCullough PA; Palevsky PM; Seliger S; Warren SR; Peduzzi P;
Clin J Am Soc Nephrol; 2009 Feb; 4(2):361-8. PubMed ID: 19118120
[TBL] [Abstract][Full Text] [Related]
7. Importance of baseline distribution of proteinuria in renal outcomes trials: lessons from the reduction of endpoints in NIDDM with the angiotensin II antagonist losartan (RENAAL) study.
Zhang Z; Shahinfar S; Keane WF; Ramjit D; Dickson TZ; Gleim GW; Mogensen CE; de Zeeuw D; Brenner BM; Snapinn SM
J Am Soc Nephrol; 2005 Jun; 16(6):1775-80. PubMed ID: 15872078
[TBL] [Abstract][Full Text] [Related]
8. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.
Brenner BM; Cooper ME; de Zeeuw D; Keane WF; Mitch WE; Parving HH; Remuzzi G; Snapinn SM; Zhang Z; Shahinfar S;
N Engl J Med; 2001 Sep; 345(12):861-9. PubMed ID: 11565518
[TBL] [Abstract][Full Text] [Related]
9. Effects of blood pressure level on progression of diabetic nephropathy: results from the RENAAL study.
Bakris GL; Weir MR; Shanifar S; Zhang Z; Douglas J; van Dijk DJ; Brenner BM;
Arch Intern Med; 2003 Jul; 163(13):1555-65. PubMed ID: 12860578
[TBL] [Abstract][Full Text] [Related]
10. Recent advances in management of type 2 diabetes and nephropathy: lessons from the RENAAL study.
Keane WF; Lyle PA;
Am J Kidney Dis; 2003 Mar; 41(3 Suppl 1):S22-5. PubMed ID: 12612946
[TBL] [Abstract][Full Text] [Related]
11. Losartan in diabetic nephropathy.
Carswell CI; Goa KL
Drugs; 2003; 63(4):407-14; discussion 415-6. PubMed ID: 12558462
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of angiotensin II receptor blockade in elderly patients with diabetes.
Winkelmayer WC; Zhang Z; Shahinfar S; Cooper ME; Avorn J; Brenner BM
Diabetes Care; 2006 Oct; 29(10):2210-7. PubMed ID: 17003295
[TBL] [Abstract][Full Text] [Related]
13. Renin angiotensin aldosterone system blockade and renal disease in patients with type 2 diabetes. An Asian perspective from the RENAAL Study.
Chan JC; Wat NM; So WY; Lam KS; Chua CT; Wong KS; Morad Z; Dickson TZ; Hille D; Zhang Z; Cooper ME; Shahinfar S; Brenner BM; Kurokawa K;
Diabetes Care; 2004 Apr; 27(4):874-9. PubMed ID: 15047641
[TBL] [Abstract][Full Text] [Related]
14. The effect of losartan on hemoglobin concentration and renal outcome in diabetic nephropathy of type 2 diabetes.
Mohanram A; Zhang Z; Shahinfar S; Lyle PA; Toto RD
Kidney Int; 2008 Mar; 73(5):630-6. PubMed ID: 18094675
[TBL] [Abstract][Full Text] [Related]
15. Adverse effects of left ventricular hypertrophy in the reduction of endpoints in NIDDM with the angiotensin II antagonist losartan (RENAAL) study.
Boner G; Cooper ME; McCarroll K; Brenner BM; de Zeeuw D; Kowey PR; Shahinfar S; Dickson T; Crow RS; Parving HH;
Diabetologia; 2005 Oct; 48(10):1980-7. PubMed ID: 16082528
[TBL] [Abstract][Full Text] [Related]
16. An economic evaluation of Losartan therapy in type 2 diabetic patients with nephropathy: an analysis of the RENAAL study adapted to France.
Souchet T; Durand Zaleski I; Hannedouche T; Rodier M; Gaugris S; Passa P;
Diabetes Metab; 2003 Feb; 29(1):29-35. PubMed ID: 12629445
[TBL] [Abstract][Full Text] [Related]
17. Advances in the treatment of diabetic renal disease: focus on losartan.
Rayner B
Curr Med Res Opin; 2004 Mar; 20(3):333-40. PubMed ID: 15025842
[TBL] [Abstract][Full Text] [Related]
18. Use of losartan in diabetic patients in the primary care setting: review of the results in LIFE and RENAAL.
Egan B; Gleim G; Panish J
Curr Med Res Opin; 2004 Dec; 20(12):1909-17. PubMed ID: 15701209
[TBL] [Abstract][Full Text] [Related]
19. The role of angiotensin II antagonism in type 2 diabetes mellitus: a review of renoprotection studies.
Zanella MT; Ribeiro AB
Clin Ther; 2002 Jul; 24(7):1019-34. PubMed ID: 12182249
[TBL] [Abstract][Full Text] [Related]
20. Losartan: lessons learned from the RENAAL study.
Shahinfar S; Lyle PA; Zhang Z; Keane WF; Brenner BM
Expert Opin Pharmacother; 2006 Apr; 7(5):623-30. PubMed ID: 16553578
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
